Medicenna Therapeutics Corp. (TSE:MDNA – Get Free Report)’s stock price rose 23.6% on Friday . The stock traded as high as C$1.31 and last traded at C$1.31. Approximately 192,493 shares traded hands during mid-day trading, an increase of 338% from the average daily volume of 43,917 shares. The stock had previously closed at C$1.06.
Medicenna Therapeutics Stock Performance
The company has a market cap of C$131.79 million, a PE ratio of -9.88 and a beta of 2.66. The company has a debt-to-equity ratio of 0.88, a quick ratio of 4.65 and a current ratio of 11.40. The firm’s 50 day moving average is C$1.02 and its 200-day moving average is C$0.98.
Medicenna Therapeutics Company Profile
Medicenna Therapeutics Corp is a Canada based immuno-oncology company. Its principal business activity is the development and commercialization of Empowered Cytokines and Superkines for the treatment of cancer. The company is engaged in developing Interleukin-4 Empowered Cytokines that specifically target the Interleukin-4 Receptor which is over-expressed by 20 different cancers, cancer stem cells and immunosuppressive cells of the tumor microenvironment.
Read More
- Five stocks we like better than Medicenna Therapeutics
- What Are Dividends? Buy the Best Dividend Stocks
- Tractor Supply Stock Looks Like a Buy-and-Hold Winner
- Utilities Stocks Explained – How and Why to Invest in Utilities
- 3 Stocks Well Below 52-Week Highs Poised for a Q4 Rebound
- The 3 Best Fintech Stocks to Buy Now
- Big Banks Are Setting the Tone as Earnings Season Kicks Off
Receive News & Ratings for Medicenna Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Medicenna Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
